United Therapeutics (UTHR) Retained Earnings (2009 - 2026)

United Therapeutics has disclosed Retained Earnings across 18 years of filings, most recently posting -$10.2 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$10.2 million, down 100.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.2 million (down 100.14% YoY), and the FY2025 annual result was $900000.0, down 99.99% from the prior year.
• Retained Earnings came in at -$10.2 million for Q1 2026 at United Therapeutics, down from $900000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $8.2 billion in Q3 2025 to a low of -$55.5 million in Q4 2022.
• The 5-year median for Retained Earnings is $4.7 billion (2022), against an average of $3.7 billion.
• Across the five-year window, Retained Earnings slumped 101.29% in 2022 and surged 110610.81% in 2025, its largest moves.
• United Therapeutics' Retained Earnings stood at -$55.5 million in 2022, then surged by 76.94% to -$12.8 million in 2023, then surged by 56523.44% to $7.2 billion in 2024, then slumped by 99.99% to $900000.0 in 2025, then sank by 1233.33% to -$10.2 million in 2026.
• The last three Retained Earnings figures came in at -$10.2 million (Q1 2026), $900000.0 (Q4 2025), and $8.2 billion (Q3 2025), per Business Quant data.